The MMT4 study was designed to explore an intensive chemotherapy regimen (MMT4- 2 with stem cell rescue. The CEV combination was evaluated as a window study. Surgery followed the second cycle. Radiotherapy was administered to post-surgical residual disease. The response rate was 55% after CEV, rising to 80% after the first CEVAIE. Twenty-five patients achieved complete remission (CR). Overall, the 5-year EFS was 22.6%: 36.4% and 15% for patients treated according to MMT4-89 and MMT4-91, respectively (P = 0.3). Local control was achieved in 77% of irradiated patients vs 45% of non-irradiated. Age Ͼ10 years was associated with significantly poorer outcome (P = 0.04). In conclusion, despite the high CR rate, intensive chemotherapy with or without high-dose melphalan appeared to have little impact on the survival of patients with metastatic extraosseus PNET.
Peripheral neuroectodermal tumor (PNET) and Ewing sarcoma are histologically similar and share the same chromosomal translocation t (11;22) , and they are therefore grouped with the Ewing family of tumors. They are considered very aggressive tumors, but the advent of effective multimodality therapy has improved the prognosis over time and the 5 year survival is reported to be around 60%. [1] [2] [3] [4] Unfortunately, survival in patients with metastatic disease at diagnosis has not improved despite aggressive treatment. 4 Traditionally, pediatric PNET and Ewing sarcoma arising outside of the bone have been included in soft tissue sarcoma protocols in many European countries. 5, 6 Extraosseous PNET has been shown to respond to the same drugs as used for rhabdomyosarcoma, such as combinations including vincristine, anthracyclines, cyclophosphamide and ifosfamide. 1, 5, 7 Platinum-based regimens are also known to be active in soft tissue sarcoma although there is not extensive experience in Ewing's family tumors, especially for carboplatin. 8, 9 In 1989 a collaborative study, MMT4, for pediatric patients with metastatic soft tissue sarcoma was launched by three European Groups including SIOP (International Society of Pediatric Oncology), ICG (Italian Cooperative Group on Childhood Soft Tissue Sarcoma) and CWS (German Cooperative Soft Tissue Sarcoma Study) exploring the efficacy of a novel drug combination. In 1991, the protocol was amended to investigate the role of high-dose chemotherapy with stem cell rescue. The results in patients with rhabdomyosarcoma have recently been published. 10 Here, we report the outcome of patients with extraosseous PNET included in MMT4 protocols.
Patients and methods
Between 1989 and 1995 37 patients were registered into the Intergroup European Studies, MMT4-89 and MMT4-91. Patients were recruited mainly from Italy (38%) and the UK (25%). Four patients were excluded from the analysis because adequate data on their treatment were not provided, one was lost to follow-up shortly after diagnosis and one was excluded because of prior treatment. Thus, 31 patients were considered eligible. Histology was centrally reviewed by the panels of each group. The primary tumor extent was assessed according to the TNM pretreatment staging system. The TNM T1 refers to tumors confined to the organ or tissue of origin, while T2 lesions invade contiguous structures; T1 and T2 groups are further divided into A or B according to tumor diameter р or Ͼ5 cm, respectively.
The treatment has been previously described. 10 The first protocol MMT4-89 explored an intensive regimen including most of the drugs active in soft tissue sarcomas. Treatment consisted of four identical 9-week cycles. Each cycle consisted of a combination of six drugs 'CEVAIE' as shown in Figure 1 . In 1991 the protocol was modified (MMT4-91) to evaluate the potential of high-dose melphalan as consolidation therapy for patients in first complete remission. The fourth cycle was replaced by melphalan, 200 mg/m 2 i.v., with autologous bone marrow or peripheral blood stem cell rescue. Bone marrow harvest or PBSC collection was performed after the second or third cycle. Second-look surgery was planned, if feasible, after the second CEVAIE cycle. This was followed by radiotherapy where there was post-surgical residual disease either in the primary or metastatic site. A total dose of 40 Gy was recommended in the case of microscopic residue, with a boost to 54.4 Gy in patients with macroscopic residue.
Because there was no experience in pediatric soft tissue sarcoma of the combination of carboplatin plus epirubicin, response at both primary and metastatic site was evaluated at day 20 after CEV administration as a formal phase II window study. There was a reassessment after every CEVAIE cycle. This was carried out clinically and radiologically and included both primary tumor and metastases (including X-ray, CT scan and ultrasound). Standard response criteria were as follows: complete response (CR), complete clinical and radiological response; partial response (PR), greater than 50% decrease in the sum of the products of the maximum perpendicular diameters of all measurable lesions; heterogeneous response (HR), PR at one or more sites with less than PR at other sites but not progressive disease; OR objective response (OR), greater than 25% but less than 50% reduction in tumor size; no response (NR), less than 25% reduction in tumor size; progressive disease (PD), increase of tumor size in any lesion.
Survival curves were calculated according to the KaplanMeier method. The overall survival (OS) curve was calculated considering the time interval between the date of diagnosis and the date of last follow-up or death from any cause. For event-free survival (EFS) the interval between diagnosis and the date of last follow-up, relapse or death was considered.
Results

Clinical characteristics
Eleven patients were treated according to the MMT89 protocol and 20 with the subsequent modified version (MMT91). Clinical characteristics according to treatment received are listed in Table 1 . Median age was 11.2 years (range 1.2 to 18.9 years). Seventeen patients were males. Most patients were diagnosed as having PNET and only four had Ewing's sarcoma.
Primary tumor characteristics were similar in the two groups of patients with regard to size, predominantly large (>5 cm) and invasive (T2) lesions, and site, localized to the thorax (mostly chest wall) or abdomen/pelvis. One child with multiple mediastinal nodes and lung metastases had an unknown primary site. An intraspinal component was evident in five children and malignant pleural or peritoneal effusion in three.
Most patients presented with metastases in multiple organs (45%) and/or multiple lesions in the same organ. Two patients had only a single subcutaneous or lung metastasis. Three children had metastatic disease in the bone marrow alone. Lungs were the most commonly affected organ (68% of the patients), with multiple lesions in 17 children (involving both lungs in 15). Eleven patients presented with metastases in the lung alone. Pulmonary metastases were more frequent in patients treated according to the MMT91 protocol while bone lesions were slightly more common in MMT89 patients (Table 1) . Regional lymph nodes were clinically involved in five children and distant ones in six.
Response to chemotherapy
Tumor response to the CEV combination was evaluated in 18 children, and 10 PR were documented (55%). Three further patients showed an objective response, and one had a heterogeneous response with OR in the primary and PR in the lung metastases. No response was evident in four patients. Thirty children were also evaluated for chemotherapy response after the first, and 28 after the second CEVAIE. There was an increase in the response rate from 80% (five CR and 19 PR) to 93% (eight CR and 18 PR). Details are shown in Table 2 . 
Local treatment
Resection of the primary tumor was performed in three patients at diagnosis. A complete excision was achieved in only one child with a tumor confined to the soft tissue of the lumbar region. Five patients underwent surgery to metastatic lesions. One had a complete removal, with two pulmonary lesions resected along with an incomplete resection of the thoracic primary mass. A diagnostic biopsy only was performed in the remaining patients. Second surgery on the primary tumor was performed in 18 patients and was considered complete in 10. Three patients underwent resection of metastatic lesions (subcutaneous tissue one, and lungs two) which was complete in all cases. Radiotherapy was administered to 13 patients with an apparent difference in the two studies. In MMT89 64% received radiotherapy compared to 35% in MMT91. This difference was due to a combination of factors and not to a systematically different approach to local treatment in the two studies. In two cases radiotherapy was omitted despite residual disease due to local center decisions and in three it was given despite tumor complete remission. Furthermore, three of these patients were very young, being less than 5 years old at diagnosis. Radiotherapy was mainly given to the site of the primary tumor with only one patient receiving lung irradiation. Doses ranged from 30 to 55 Gy (median 40). All patients with tumor localized to head, neck and extremities were irradiated, compared to only five (45%) and three (27%) of those with thoracic and abdominal tumors.
Megatherapy
High-dose chemotherapy was administered to 13 of the 20 patients enrolled in the MMT91 study. Six children were taken off protocol before high-dose chemotherapy was scheduled because of toxicity (two) or tumor relapse or progression (four). The reason for exclusion is unknown in one patient. At the beginning of high-dose therapy 11 patients were in CR and two in PR. One of these latter patients received high-dose carboplatin plus busulphan instead of melphalan and achieved a CR. Bone marrow harvest was performed in seven patients and peripheral blood stem cell collection in four. The source of stem cells was unreported in two cases.
Toxicity
Myelosuppression was the most notable side-effect of CEVAIE, with 71% of patients developing grade III or IV neutropenia, and 58% developing grade III or IV thrombocytopenia. Three patients died from treatment-related complications. Two died in CR from interstitial pneumonitis and fungal sepsis, respectively. One died after developing renal failure and uncontrollable seizures attributed to ifosfamide, shortly after the beginning of the second CEVAIE course. In contrast, high-dose melphalan did not cause any unexpected problems. Toxicity was mainly hematological and no deaths were reported.
Outcome
Overall, 25 patients achieved a CR, which was histologically confirmed at the primary site in nine. Six patients are currently alive in first CR, 5 to 10 years (median 6) from diagnosis. One patient is alive in second CR 5 years after a local relapse treated with radiotherapy and further chemotherapy. One patient is alive with disease 2 years after local relapse. Nine children had local recurrence (with additional metastases in three patients), two developed regional recurrence (one with metastases), seven relapsed with metastases and in four there was tumor progression on initial therapy.
As described above there were three treatment-related deaths.
The 5 year OS and EFS for the 31 patients enrolled in the two studies were 32.2% (95% confidence interval (CI) 16.9-48.6) and 22.6% (95% CI, 10-38.3), respectively. The OS rate for the patients treated according to the MMT89 protocol was 45.5% compared with 25% for the patients enrolled into the MMT91 protocol (P = 0.3; Figure 2a ). The corresponding 5 year EFS rates were 36.4% and 15% (P = 0.3, Figure 2b ). No significant differences were noted in the EFS of irradiated vs non-irradiated patients (30.8 vs 16.7, P = 0.2). However, without considering patients who progressed or experienced toxicity during the treatment, local control was maintained in 77% of irradiated patients and 45% in non-irradiated patients.
The 5 year OS rate for patients less than 10 years old was 63.6% compared with 15% for the older patients (P = 0.02, Figure 3a) . A smaller but still significant advantage for younger patients was also evident in the EFS rates being 36.4% vs 15% (P = 0.04, Figure 3b ). It is also worth mentioning that three out of 6 patients with an extremity primary are alive with no evidence of disease compared to 3 out of 22 with axial primary tumor but this difference did not reach statistical significance (P = 0.09). The number and site of metastases did not influence outcome. Only two out of 11 patients with lung metastases alone remain alive disease-free.
Discussion
In 1989 European Groups decided to use a common protocol in children with metastatic sarcoma. This was based on the alternating administration of different agents in an attempt to overcome drug resistance. The six-drug regimen gave initial excellent results in metastatic rhabdomyosarcoma with a 53% response rate after only one course of the CEV combination and 55% patients in CR after two course of the CEVAIE regimen with or without surgery. Unfortunately, this did not result in better survival of the patients in comparison to the previous European experience, 12 or that of the Intergroup Rhabdomyosarcoma Study (IRS) Group. 7 Similar results were achieved in PNET with a 55% response rate after the initial CEV and 93% after two CEVAIE administrations. The overall CR rate of 80.5% achieved in this study compares favorably with the 56% CR rate achieved in the IRS studies with more conventional doses of chemotherapy.
This increase in CR rate has been reported in other stud- ies when more intensive treatment is administered 13, 14 although direct comparison may be difficult because these studies mainly include patients with bony Ewing's sarcoma. Seven out of eight patients with metastatic PNET treated with the VADRIAC regimen achieved CR. 3 Kushner et al 13 have reported a 67% CR rate in 12 patients with metastatic PNET or Ewing's treated with the P6 protocol based on dose intensification of cyclophosphamide in combination with vincristine and doxorubicin alternating with ifosfamide and etoposide. Felgenhauer et al 14 employed a combination of five drugs given concomitantly (VACIME) in an attempt to prevent the emergence of cell chemoresistance. They have reported an 83% overall CR rate. Unfortunately, the high CR rate did not translate into a better final outcome. Miser et al 3 have reported an actuarial relapse-free survival of 56% at 12 months but only 14% at 6 years. 15 The 42% EFS rate reported by Kushner et al 13 should be regarded cautiously because the median follow-up was only 17 months. Felgenhauer et al 14 reported a similar 45% EFS at 4 years but in a mixed group of tumors with regional or metastatic disease including RMS, Ewing/PNET, undifferentiated sarcoma, anaplastic Wilms and malignant peripheral nerve sheath tumors.
Our results do not seem convincingly better than those reported by the IRS group using a more conventional approach: in a group of 16 children with metastatic extraosseous Ewing, five patients were long-term survivors (median follow up 5.8 years). 7 Different hypotheses may explain this disappointing result. Metastatic PNET is an aggressive disease with rapid onset of chemotherapy resistance and this was not prevented, even by the potentially non-cross-resistant CEVAIE regimen. Another reason may be that the inclusion of multiple agents compromised the optimal administration of the most active drugs leading to a reduction of their dose intensity. An attempt to administer multiple chemotherapeutic agents concomitantly, as in the VACIME regimen, did not produce better results and toxicity was of major concern, with one toxic death and three patients removed from the study. 14 The apparently high toxicity rate of CEVAIE (10%) is of some concern. Three patients died of treatment-related complications during the initial part of our study. This was unexpected as the rate of toxic death was 3.4% in 175 patients with metastatic RMS treated on the same protocol. The small number of patients and the multicenter setting may explain an overestimation of the toxicity.
Local control may also be important in metastatic patients. 13 As in other studies, aggressive delayed resection was part of our treatment, 13,14 but radiotherapy was not administered in more than 50% of patients. The local failure in the present study appears to be higher than in previously published studies which may be a consequence of this omission. Horowitz et al 15 reported no isolated local relapses in a series of 49 metastatic pediatric sarcomas and Raney et al 7 only one in the nine Ewing patients who achieved a CR when radiotherapy had been delivered routinely to all sites of initial disease.
High-dose chemotherapy remains an investigational strategy for the treatment of childhood solid tumors. This strategy has been applied to different pediatric cancers with Bone Marrow Transplantation evidence of feasibility but not efficacy. Benefit has been shown in the treatment of metastatic neuroblastoma 16 and, recently, promising results have also been reported in adult patients with advanced soft tissue sarcoma. 17 In children, previous experience failed to show a better outcome for metastatic rhabdomyosarcoma 10, 18 or bony Ewing's sarcoma. 19 In the MMT4 studies there was evidence that high-dose consolidation therapy with melphalan may have delayed relapse but it did not ultimately improve the survival of patients with metastatic rhabdomyosarcoma. 10 This conclusion has been confirmed in the group of patients with metastatic soft tissue PNET. However, the reduced use of local radiotherapy in the patients who were candidates for dose intensification may have undermined the efficacy of this strategy.
The search for prognostic factors is difficult in a small group of patients, however, the impact of age emerged from our analysis, as observed in patients with metastatic RMS 20, 21 or bony Ewing's sarcoma. 22 No other factors showed prognostic value. Prognosis in bony Ewing's seems better when metastases are limited to the lung, with survivals approaching 30% in a large series. 23 In our series, only two out of 11 patients with metastases limited to the lungs were long-term survivors.
In conclusion, an aggressive chemotherapy regimen based on alternating drugs with or without high-dose melphalan did not significantly improve survival of patients with metastatic extraosseus PNET despite high CR rates. Alternative strategies are required, perhaps with novel highdose regimens or alternative drug scheduling. The importance of local radiotherapy should not be underestimated.
